MedImmune completes purchase of fifth Gyrolab system to further expand therapeutic antibody development at their west-coast Hayward facility


Gyros AB, the leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the sale of a fifth Gyrolab™ system to MedImmune. This additional system will be installed at the company’s Hayward facility. Previously installed Gyrolab systems are in use at MedImmune’s facilities in Gaithersburg, USA and Cambridge, UK.

“Not only is this a huge vote of confidence that Gyrolab continues to add significant value to the drug discovery and development workflow but it also underlines a trend that is evident within the industry,” stated Erik Walldén, CEO and president of Gyros. “We are seeing that it’s actually the biotech companies – like MedImmune, Amgen and ThromoboGenics all with multiple systems – who are leading the way by implementing Gyrolab to shorten project times, increase efficiency and increase their competiveness in the race to deliver new protein-based therapeutics. These organizations understand that the added benefits that Gyrolab delivers are vital to become more productive.”

“The key reasons for the purchase of the existing systems within the MedImmune organization have been the high throughput and reduced reagent consumption. Gyrolab reduces turnaround time so that critical decisions can be taken earlier in the process,” as stated in an earlier interview with MedImmune.

“Critical factors in this recent purchase by the Hayward facility were the extremely small sample volumes required, as little as 10 microliters, and the very broad dynamic range. Both crucial in the clinical phase of drug development,” adds Katherine Flagg VP Sales, North America at Gyros Inc.

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.